Adenocarcinoma — Research

Adenocarcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	490,877	`("Adenocarcinoma"[mh] OR "Adenocarcinomas"[mh] OR "Adenoma, Malignant"[mh] OR "Adenomas, Malignant"[mh])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	93,894	`("Adenocarcinoma"[mh] OR "Adenocarcinomas"[mh] OR "Adenoma, Malignant"[mh] OR "Adenomas, Malignant"[mh]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	15,455	`("Adenocarcinoma"[mh] OR "Adenocarcinomas"[mh] OR "Adenoma, Malignant"[mh] OR "Adenomas, Malignant"[mh]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 21 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (378)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 251–275 of 378 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
· Nat Med · 2013 · PMID 24162815 · validated civic_curation pubmed
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
· Anticancer Res · 2013 · PMID 23898052 · validated civic_curation pubmed
The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.
· Genes Dev · 2012 · PMID 22802530 · validated civic_curation pubmed
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.